Next Vial Review

Our assessment

Three of the four hardest disclosures in this comparison, all on one page: Next Vial prints the billed total beside the per-month figure on all eight of its plan cards, names the pharmacy that may fill the prescription with a street address, and publishes an actual list of the states it serves. The blemish sits further down that same page: a banner advertising a monthly rate that matches none of the plans above it and is higher than every one of them.

Eight plans, eight totals

Two medications, four plan lengths each. Every card past the first prints its billed total in the same block as its per-month figure, and the one-month card is labeled billed monthly.

So the prepayment behind each lower rate is stated rather than implied. That is the disclosure most sellers with a plan ladder leave you to work out.

The page loads on semaglutide. The dual-agonist plan set is an entirely different group of eight figures and appears only after you click the medication toggle, so anyone who doesn't touch it sees the cheaper drug throughout.

A banner that contradicts the table

Below the plan cards, a promotional block advertises doctor-led plans as low as a specific monthly figure. That figure is not any of the eight plan rates, and it is higher than every one of them, including the one-month rate on the more expensive drug.

Nothing on the page reconciles the two. Arrive mid-scroll and you get a worse number than the one printed above you, described as the best available.

Pharmacy, network and states

The FAQ names the pharmacy that may fill a prescription, with a street address, a phone number and its hours. It names the physician network separately and links to it. And it answers the service-area question with a list of state names rather than a nationwide claim.

That list runs to forty-nine states. Alaska is absent, and the answer never says so — it simply reads as a list of the states served. If you live there, you have to spot the omission yourself.

Compounded, with no membership

The priced panel states there is no monthly membership fee, and the footer explains at length that compounded medications are not FDA-reviewed and are prepared under the relevant federal provision on a patient-specific prescription.

There is no brand-name lane. No individual prescriber is named — the disclosure stops at the network. The catalog alongside the GLP-1 page carries a wide range of other therapies, which is worth knowing if a narrow weight-loss practice is what you want.